2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T
Why now
Thesis: Very early CAR-T data, no investable read
Catalyst to watch: Larger trial enrollment
Main risk: Tiny sample, unproven efficacy
Why it matters
Early Phase 1 CAR-T data in 9 patients is too preliminary to move biotech indices.
Details
— Poster presentation selected for the poster discussion session (Abstract No.: PA-200): in a first-in-human study in 9 heavily pretreated, high-risk patients with relapsed/refractory multiple myeloma or plasma cell leukemia, RD140, a fully human BCMA/GPRC5D dual-targeted FasT CAR-T,...
Sources
- prnewswire · 2026-09-25 15:32 UTC